Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands.
The Rotterdam Eye Hospital, Rotterdam, The Netherlands.
Acta Ophthalmol. 2022 Feb;100(1):e38-e46. doi: 10.1111/aos.14865. Epub 2021 Apr 8.
Approximately twenty per cent of Von Hippel-Lindau patients with retinal haemangioblastomas (RH) suffer from visual impairment. Various treatment options are available for peripheral RH. However, management of peripheral RH is complex due to multifocality and bilaterality.
To summarize published evidence on efficacy and safety of different interventions for peripheral RH and to provide treatment recommendations for specialists.
Comprehensive searches were performed using Medline, Embase, Web of Science and Google Scholar database on 4 March 2020. English publications that described outcomes related to efficacy or complications in at least two patients with peripheral RH were included. Efficacy and safety were estimated by complete tumour eradication rate, pretherapeutic and treatment-related complication rate. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to calculate the risk estimate of complications between treatment options.
Twenty-seven articles were included in this review describing nine different treatment options for peripheral RH: laser photocoagulation (n = 230), cryotherapy (n = 50), plaque radiotherapy (n = 27), vitreoretinal surgery (n = 88), photodynamic therapy (PDT; n = 14), transpupillary thermotherapy (TTT; n = 10), external beam radiotherapy (n = 3), systemic treatment (n = 7) and intravitreal anti-VEGF (n = 2). Complete tumour eradication was achieved in 86.7% (95% CI: 83.5-89.9%) of all eyes. For the different treatments, this was after laser photocoagulation 89.9% (86.1-93.7%), cryotherapy 70.2% (57.0-83.4%), plaque radiotherapy 96.3% (89.1-100.0%), vitreoretinal surgery (100.0%), PDT 64.3% (38.3-90.3%) and TTT 80.0% (53.8-100.0%). No complete tumour eradication was achieved after systemic therapy, external beam radiotherapy or intravitreal anti-VEGF. Photodynamic therapy and vitreoretinal surgery showed the highest complication rate after treatment compared to the other treatments (OR 10.5 [95% CI: 2.9-38.4]) and (OR 5.9 [95% CI: 3.4-9.9]), respectively. Cases that had pretherapeutic complications showed a higher treatment-related complication rate (OR 14.8 [95% CI: 7.3-30.0]) than cases without complications before treatment.
These findings suggest that laser photocoagulation is the safest and most effective treatment method for peripheral RH up to 1.5 mm in diameter. Vitreoretinal surgery has the highest success rate for complete tumour eradication and may be the most suitable treatment option in the presence of pretherapeutic complications and for larger tumours.
大约 20%的患有视网膜血管母细胞瘤(RH)的 von Hippel-Lindau 患者有视力障碍。对于周边 RH 有多种治疗选择。然而,由于多发性和双侧性,周边 RH 的治疗很复杂。
总结不同干预措施治疗周边 RH 的疗效和安全性的已有证据,并为专家提供治疗建议。
于 2020 年 3 月 4 日使用 Medline、Embase、Web of Science 和 Google Scholar 数据库全面检索,纳入至少有 2 例周边 RH 患者疗效或并发症相关结局的英文文献。通过完全肿瘤消除率、治疗前和治疗相关并发症发生率来评估疗效和安全性。计算治疗方案之间并发症风险估计的比值比(OR)和 95%置信区间(CI)。
本综述纳入了 27 篇文章,描述了周边 RH 的 9 种不同治疗方法:激光光凝术(n=230)、冷冻疗法(n=50)、贴敷放疗(n=27)、玻璃体视网膜手术(n=88)、光动力疗法(PDT;n=14)、经瞳孔温热疗法(TTT;n=10)、外照射放疗(n=3)、全身治疗(n=7)和玻璃体内抗-VEGF(n=2)。所有眼睛的完全肿瘤消除率为 86.7%(95%CI:83.5-89.9%)。对于不同的治疗方法,激光光凝术为 89.9%(86.1-93.7%),冷冻疗法为 70.2%(57.0-83.4%),贴敷放疗为 96.3%(89.1-100.0%),玻璃体视网膜手术为 100.0%,PDT 为 64.3%(38.3-90.3%),TTT 为 80.0%(53.8-100.0%)。全身治疗、外照射放疗或玻璃体内抗-VEGF 均未达到完全肿瘤消除。与其他治疗方法相比,PDT 和玻璃体视网膜手术的治疗后并发症发生率最高(OR 10.5[95%CI:2.9-38.4])和(OR 5.9[95%CI:3.4-9.9])。与治疗前无并发症的病例相比,治疗前有并发症的病例治疗相关并发症发生率更高(OR 14.8[95%CI:7.3-30.0])。
这些发现表明,对于直径不超过 1.5mm 的周边 RH,激光光凝术是最安全和最有效的治疗方法。玻璃体视网膜手术的完全肿瘤消除率最高,对于治疗前有并发症和较大肿瘤,可能是最适合的治疗选择。